Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response

Abstract

Background/Aim: The role of neoadjuvant chemotherapy (NACT) is under investigation in locally advanced cervical cancer (LACC). Patients and Methods: A total of 49 patients with FIGO stage IB1-IIB cervical cancer who underwent two different regimens of weekly dose-dense NACT were included. The objective was to evaluate clinical/pathological response and toxicity profile. Results: A clinical complete response and partial response were obtained in 43 patients with a clinical overall response rate of 88%. Among the 42 surgically treated patients, 7 (17%) and 35 (83%) achieved a pathological overall optimal response and a suboptimal pathological response, respectively. G3-G4 neutropenia occurred in 16% of patients, whereas no cases of G3 thrombocytopenia, G3 anemia and febrile neutropenia were observed. Conclusion: Dose-dense NACT is safe, has acceptable toxicity, and obtains good clinical response, but is less effective in terms of pathological overall optimal response rates compared to other regimens. Patients and MethodsThe study was approved by the appropriate Institutional Review Board (IRB) and written informed consent was obtained from all subjects. Data were extracted from two Italian oncological reference centers database (

Effects of neoadjuvant chemotherapy combined with radical laparoscopic surgery with quality nursing care on clinical efficacy and sex hormones in patients with cervical cancer

“…Consequently, this resulted in a noticeable decrease in SCC-Ag, CEA, and CA125 levels in patients undergoing combined treatment. Additionally, while surgery focuses on the mechanical removal of the tumor, neoadjuvant chemotherapy effectively inhibits and destroys cancer cells at a molecular level [20].…”

Comparison of the clinical efficacy of paclitaxel + carboplatin and paclitaxel + cisplatin on tumor markers and WHOQOL-BREF score on cervical cancer patients

“…Clinical studies consistently reported low 5-year survival rates among cervical cancer patients, regardless of whether surgery or radiation therapy was utilized, suggesting a substantial need for improved efficacy in both surgical and radiation treatments [9,10]. Previously, chemotherapy was seldom prescribed in the clinical treatment of cervical cancer patients due to the prevailing belief that cervical cancer lesions exhibited limited sensitivity to chemotherapeutic agents [11,12]. However, with the introduction of neoadjuvant chemotherapy in cervical cancer treatment, researchers across multiple locations have begun to further assess this treatment approach by conducting in-depth analyses of specific neoadjuvant chemotherapy regimens used for cervical cancer treatment, including the optimal types and dosages of chemotherapeutic agents.…”

Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma

“…In addition to ovarian carcinoma, NAC has been utilized for the management of other malignancies, including carcinomas of the breast, lung, stomach, and rectum (23)(24)(25)(26)(27); its effects on the histomorphology of these tumors have been well documented (12,13,20,21). Chemotherapy-induced morphological changes in the ovary have been described in several studies.…”